NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03141177,A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT03141177,CheckMate 9ER,ACTIVE_NOT_RECRUITING,The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma,YES,Renal Cell Carcinoma,BIOLOGICAL: Nivolumab|DRUG: Cabozantinib|DRUG: Sunitinib|BIOLOGICAL: Ipilimumab,"Progression Free Survival (PFS), PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)","Overall Survival (OS), Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or ""last known alive date"")., From randomization date to death date (Up to 31 months)|Objective Response Rate (ORR), Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants.

Complete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions., Up to 31 Months|Number of Participants Experiencing Adverse Events (AEs), Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame., From first dose to 100 days following last dose (Up to 32 Months)|Number of Participants Experiencing Serious Adverse Events (SAEs), Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame., From first to dose to 100 days following last dose (Up to 32 months)|Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation, Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame., From first dose to 30 days following last dose (Up to 30 months)|Number of Deaths, Number of deaths due to any cause during the specified time frame., From first dose to (up to 31 months) following first dose|Number of Participants With Laboratory Abnormalities, Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame., From first dose to 30 days following last dose (Up to 30 Months)|Number of Participants With Laboratory Values Grade Shifting From Baseline, Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame., From first dose to 30 days following last dose (Up to 30 Months)",,Bristol-Myers Squibb,Exelixis|Ono Pharmaceutical Co. Ltd,ALL,"ADULT, OLDER_ADULT",PHASE3,701,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CA209-9ER|2017-000759-20,2017-08-22,2020-02-12,2024-04-17,2017-05-04,2022-04-26,2024-01-17,"Local Institution - 0077, Daphne, Alabama, 36526, United States|Local Institution - 0044, Goodyear, Arizona, 85338, United States|Local Institution - 0132, Tucson, Arizona, 85724-5024, United States|Local Institution - 0133, Bakersfield, California, 93309, United States|Local Institution - 0093, Los Angeles, California, 90404, United States|Local Institution - 0090, Redondo Beach, California, 90277, United States|Local Institution - 0088, San Luis Obispo, California, 93401, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, 93454, United States|Local Institution - 0103, Aurora, Colorado, 80045, United States|Local Institution - 0127, Athens, Georgia, 30607, United States|Local Institution - 0086, Newnan, Georgia, 30265, United States|Local Institution - 0036, Chicago, Illinois, 60612, United States|Local Institution - 0042, Zion, Illinois, 60099, United States|Local Institution - 0091, Fort Wayne, Indiana, 46804, United States|Local Institution - 0087, Wichita, Kansas, 67214, United States|Local Institution - 0113, Boston, Massachusetts, 02114, United States|Local Institution - 0037, Boston, Massachusetts, 02215, United States|Local Institution - 0106, Kansas City, Missouri, 64132, United States|Local Institution - 0035, Saint Louis, Missouri, 63110, United States|Local Institution - 0102, Las Vegas, Nevada, 89169, United States|Local Institution - 0040, Buffalo, New York, 14263, United States|Local Institution - 0017, New York, New York, 10065, United States|Local Institution - 0067, Portland, Oregon, 97239, United States|Local Institution - 0135, Allentown, Pennsylvania, 18105, United States|Local Institution - 0105, Nashville, Tennessee, 37203, United States|Local Institution - 0075, Dallas, Texas, 75246, United States|Local Institution - 0068, Houston, Texas, 77030, United States|Local Institution - 0080, San Antonio, Texas, 78240, United States|Local Institution - 0078, Sherman, Texas, 75090, United States|Local Institution - 0131, Norfolk, Virginia, 23502, United States|Local Institution - 0046, Caba, Buenos Aires, C1120AAT, Argentina|Local Institution - 0048, Ciudad Autonoma De Buenos Aire, Buenos Aires, 1181, Argentina|Local Institution - 0114, Viedma, RIO Negro, 8500, Argentina|Local Institution - 0138, Caba, 1426, Argentina|Local Institution - 0050, Cordoba, 5000, Argentina|Local Institution - 0049, Cordoba, X5004FHP, Argentina|Local Institution - 0047, Tucuman, 4000, Argentina|Local Institution - 0002, North Ryde, New South Wales, 0, Australia|Local Institution - 0008, Sydney, New South Wales, 2010, Australia|Local Institution - 0009, Sydney, New South Wales, 2139, Australia|Local Institution - 0073, Westmead, New South Wales, 2145, Australia|Local Institution - 0006, Herston, Queensland, 4006, Australia|Local Institution - 0001, Southport, Queensland, 4215, Australia|Local Institution - 0004, Elizabeth Vale, South Australia, 5112, Australia|Local Institution - 0005, Malvern, Victoria, 3144, Australia|Local Institution - 0007, Doubleview, Western Australia, 6018, Australia|Local Institution - 0129, South Brisbane, 4101, Australia|Local Institution - 0057, Belo Horizonte, Minas Gerais, 30130-090, Brazil|Local Institution - 0119, Ijui, RIO Grande DO SUL, 98700-000, Brazil|Local Institution - 0056, Porto Alegre, RIO Grande DO SUL, 90610-000, Brazil|Local Institution - 0060, Porto Alegre, RIO Grande DO SUL, 91350-200, Brazil|Local Institution - 0058, Barretos, Sao Paulo, 14784-400, Brazil|Local Institution - 0066, Rio De Janeiro, 20231-050, Brazil|Local Institution - 0074, Sao Paulo, 01323-020, Brazil|Local Institution - 0061, Sao Paulo, 05651901, Brazil|Local Institution - 0045, Santiago, Metropolitana, 8420383, Chile|Local Institution - 0034, Hradec Kralove, 500 05, Czechia|Local Institution - 0033, Olomouc, 779 00, Czechia|Local Institution - 0013, Aachen, 52074, Germany|Local Institution - 0016, Bonn, 53127, Germany|Local Institution - 0117, Essen, 45136, Germany|Local Institution - 0023, Jena, 07747, Germany|Local Institution - 0010, Muenchen, 81675, Germany|Local Institution - 0014, Nuernberg, 90419, Germany|Local Institution - 0011, Tuebingen, 72076, Germany|Local Institution - 0082, Athens, 11528, Greece|Local Institution - 0083, Thessaloniki, 546 45, Greece|Local Institution - 0072, Haifa, 3109601, Israel|Local Institution - 0070, Kfar Saba, 44281, Israel|Local Institution - 0071, Petah Tikva, 49414, Israel|Local Institution - 0069, Ramat Gan, 52621, Israel|Local Institution - 0054, Arezzo, 52100, Italy|Local Institution - 0052, Milano, 20132, Italy|Local Institution - 0055, Napoli, 80131, Italy|Local Institution - 0053, Padova, Padova, Italy|Local Institution - 0051, Pavia, 27100, Italy|Local Institution - 0147, Pavia, 27100, Italy|Local Institution - 0172, Terni, 05100, Italy|Local Institution - 0148, Akita-shi, Akita, 010-8543, Japan|Local Institution - 0157, Sapporo-shi, Hokkaido, 0608648, Japan|Local Institution - 0164, Sapporo, Hokkaido, 0608543, Japan|Local Institution - 0168, Kobe, Hyogo, 6500017, Japan|Local Institution - 0159, Morioka, Iwate, 0208505, Japan|Local Institution - 0171, Yokohama, Kanagawa, 236-0004, Japan|Local Institution - 0166, Yokohama, Kanagawa, 241-8515, Japan|Local Institution - 0150, Niigata-shi, Niigata, 9518520, Japan|Local Institution - 0169, Okayama-shi, Okayama, 7008558, Japan|Local Institution - 0154, Osaka, Osaka-shi, 545-8586, Japan|Local Institution - 0170, Osaka-shi, Osaka, 5418567, Japan|Local Institution - 0160, Osakasayamashi, Osaka, 5898511, Japan|Local Institution - 0163, Suita-shi, Osaka, 565-0871, Japan|Local Institution - 0155, Hidaka-shi, Saitama, 3501298, Japan|Local Institution - 0153, Tokushima-shi, Tokushima, 7708503, Japan|Local Institution - 0152, Adachi-ku, Tokyo, 123-8558, Japan|Local Institution - 0158, Bunkyo-ku, Tokyo, 1138519, Japan|Local Institution - 0151, Bunkyo-ku, Tokyo, 1138603, Japan|Local Institution - 0173, Minato-ku, Tokyo, 1058470, Japan|Local Institution - 0156, Aomori, 0368563, Japan|Local Institution - 0167, Chiba, 260-8717, Japan|Local Institution - 0161, Fukuoka, 812-8582, Japan|Local Institution - 0162, Nagasaki, 8528501, Japan|Local Institution - 0149, Tokyo, 160-8582, Japan|Local Institution - 0165, Yamagata, 9909585, Japan|Local Institution - 0062, Ciudad de Mexico, Distrito Federal, 06100, Mexico|Local Institution - 0116, Mexico, Distrito Federal, 14080, Mexico|Local Institution - 0115, Tlalpan, Distrito Federal, 14080, Mexico|Local Institution - 0108, Zapopan, Jalisco, 45070, Mexico|Local Institution - 0065, Monterrey, Nuevo Leon, 64000, Mexico|Local Institution - 0143, Monterrey, Nuevo LEON, 64060, Mexico|Local Institution - 0064, Monterrey, Nuevo Leon, 64460, Mexico|Local Institution - 0136, Merida, Yucatan, 97125, Mexico|Local Institution - 0063, Queretaro, 76000, Mexico|Local Institution - 0084, Biala Podlaska, 21-500, Poland|Local Institution - 0130, Bydgoszcz, 85796, Poland|Local Institution - 0085, Gdansk, 80-219, Poland|Local Institution - 0021, Cluj-Napoca, 400015, Romania|Local Institution - 0022, Craiova, 200542, Romania|Local Institution - 0020, Moscow, 125284, Russian Federation|Local Institution - 0099, Saint-Petersburg, 197758, Russian Federation|Local Institution - 0125, Barcelona, 08035, Spain|Local Institution - 0121, Madrid, 28009, Spain|Local Institution - 0120, Madrid, 28041, Spain|Local Institution - 0144, Santander, 39008, Spain|Local Institution - 0124, Sevilla, 41013, Spain|Local Institution - 0123, Valencia, 46014, Spain|Local Institution - 0107, Ankara, 06018, Turkey|Local Institution - 0139, Ankara, 06590, Turkey|Local Institution - 0094, Ankara, 06800, Turkey|Local Institution - 0096, Antalya, 07070, Turkey|Local Institution - 0097, Denizli, 20070, Turkey|Local Institution - 0095, Edirne, 22030, Turkey|Local Institution - 0146, Istanbul, 34300, Turkey|Local Institution - 0111, London, EC1A 7BE, United Kingdom|Local Institution - 0109, Manchester, M20 4BX, United Kingdom|Local Institution - 0140, Truro, TR1 3LJ, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/77/NCT03141177/Prot_002.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/77/NCT03141177/SAP_003.pdf"
